A Systems Biology Approach for Studying Heterotopic Ossification: Proteomic Analysis of Clinical Serum and Tissue Samples.
10.1016/j.gpb.2018.04.006
- Author:
Erin L CROWGEY
1
;
Jennifer T WYFFELS
2
,
3
;
Patrick M OSBORN
4
;
Thomas T WOOD
4
;
Laura E EDSBERG
5
Author Information
1. Nemours Biomedical Research, Nemours Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA.
2. Natural and Health Sciences Research Center, Center for Wound Healing Research, Daemen College, Amherst, NY 14226, USA
3. Department of Computer and Information Sciences, Center for Bioinformatics and Computational Biology, University of Delaware, Newark, DE 19711, USA.
4. San Antonio Military Medical Center, San Antonio, TX 78219, USA.
5. Natural and Health Sciences Research Center, Center for Wound Healing Research, Daemen College, Amherst, NY 14226, USA. Electronic address: ledsberg@daemen.edu.
- Publication Type:Letter
- Keywords:
Extracellular matrix organization;
Heterotopic ossification;
Keratinization;
Proteomics;
Runt-related transcription factor 2
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Biomarkers;
metabolism;
Case-Control Studies;
Female;
Humans;
Male;
Middle Aged;
Ossification, Heterotopic;
blood;
diagnosis;
metabolism;
Proteome;
analysis;
Proteomics;
methods;
Systems Biology;
methods;
Young Adult
- From:
Genomics, Proteomics & Bioinformatics
2018;16(3):212-220
- CountryChina
- Language:English
-
Abstract:
Heterotopic ossification (HO) refers to the abnormal formation of bone in soft tissue. Although some of the underlying processes of HO have been described, there are currently no clinical tests using validated biomarkers for predicting HO formation. As such, the diagnosis is made radiographically after HO has formed. To identify potential and novel biomarkers for HO, we used isobaric tags for relative and absolute quantitation (iTRAQ) and high-throughput antibody arrays to produce a semi-quantitative proteomics survey of serum and tissue from subjects with (HO) and without (HO) heterotopic ossification. The resulting data were then analyzed using a systems biology approach. We found that serum samples from subjects experiencing traumatic injuries with resulting HO have a different proteomic expression profile compared to those from the matched controls. Subsequent quantitative ELISA identified five blood serum proteins that were differentially regulated between the HO and HO groups. Compared to HO samples, the amount of insulin-like growth factor I (IGF1) was up-regulated in HO samples, whereas a lower amount of osteopontin (OPN), myeloperoxidase (MPO), runt-related transcription factor 2 (RUNX2), and growth differentiation factor 2 or bone morphogenetic protein 9 (BMP-9) was found in HO samples (Welch two sample t-test; P < 0.05). These proteins, in combination with potential serum biomarkers previously reported, are key candidates for a serum diagnostic panel that may enable early detection of HO prior to radiographic and clinical manifestations.
